title: 131I-MIBG Therapy in a Metastatic Small Bowel Neuroendocrine Tumor Patient Undergoing Hemodialysis.
abstract: Systemic radioisotope therapy with I-metaiodobenzylguanidine (I-MIBG) is an effective form of targeted therapy for neuroendocrine tumors. One of the absolute contraindications to administering I-MIBG therapy listed in the 2008 European Association of Nuclear Medicine guidelines is renal insufficiency requiring dialysis, although this contraindication is not evidence based. We describe a 68-year-old woman with a metastatic small bowel neuroendocrine tumor who developed renal insufficiency requiring hemodialysis. Imaging and dosimetry with I-MIBG were performed and showed that the radiation doses to the whole body and lungs were within safe limits. She was treated with 1820 MBq of I-MIBG with no short-term adverse reactions.
authors.affiliation: From the *Department of Internal Medicine, University of Alberta; †Department of Diagnostic Imaging, Cross Cancer Institute; and ‡Department of Endocrinology, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Behruz
authors.initials: B
authors.lastname: Rahimi
authors.forename: William
authors.initials: W
authors.lastname: Makis
authors.forename: Terence A
authors.initials: TA
authors.lastname: Riauka
authors.forename: Alexander J B
authors.initials: AJ
authors.lastname: McEwan
authors.forename: Don
authors.initials: D
authors.lastname: Morrish
mesh_terms: D019797:3-Iodobenzylguanidine / Q000627:therapeutic use*; D000368:Aged; D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000556:secondary; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D006435:Renal Dialysis
chemical_list: D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine